Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Logitech International SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $280 (market cap $39.89B), while Logitech International SA trades at $101.89 (market cap $14.65B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.7× Logitech International SA's market cap, and Logitech International SA pays a 1.67% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LOGI | |
|---|---|---|
Market Cap | $39.89B | $14.65B |
Sector | Health | Technology |
52-Week High | $491.22 | $126.69 |
52-Week Low | $278.09 | $85.84 |
Enterprise Value | $38.15B | $13.00B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Logitech (LOGI) trades at $101.95, up 0.28% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.13 exceeding the $1.10 estimate. Fundamentals show robust profitability, including a 43.2% gross margin and 32.78% ROE, while valuation ratios like P/E of 21.25 and P/S of 3.12 reflect moderate pricing. Recent news highlights partnerships, such as with Call of Duty: Modern Warfare 4, and product launches like the G3 Series, supporting growth momentum.
The outlook for LOGI is cautiously optimistic, with a consensus price target of $113.00 implying 11% upside. Opportunities include B2B expansion and AI-enabled products driving margin growth, but risks involve competitive pressures in peripherals and reliance on consumer spending. Analyst sentiment is divided, with 26% buy ratings balanced by equal sell recommendations, indicating uncertainty amid solid execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
